Remove 2023 Remove Medicare Remove Prescription Drug Pricing
article thumbnail

Magnolia Regional used price transparency IT to get more CHF patients to fill their prescriptions

Healthcare It News

"With prescription drug prices rising at every turn, patients need price transparency and the ability to discuss options with their doctors during office visits," Davis advised. ADVICE FOR OTHERS.

article thumbnail

Comments to CMS Guidance on the Medicare Prescription Drug Inflation Rebate Program Due March 11, 2023

Health Law Advisor

This feedback must be submitted to CMS by March 11, 2023 via email ( IRARebateandNegotiation@cms.hhs.gov ). Stakeholders can view CMS’s issuance of the Initial Inflation Rebate Guidances as an early step in the complex, multi-year process CMS must undertake to implement the various IRA provisions.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

article thumbnail

A Health Consumer Bill of Rights: Assuring Affordability, Access, Autonomy, and Equity

Jane Sarashon

In addition to highlighting the Patient’s Bill of Rights, NABIP’s keynotes and general sessions will speak to similar topics being brainstormed at VIVE this week — including mental health, maternal health, pharmacy and prescription drugs (pricing, PBMs), population health, and Medicare and Medicaid innovations.

ACA 118
article thumbnail

CMS Releases Guidance on Implementation of Rebate Programs for Certain Medicare Part B and Part D Drugs

Healthcare Law Blog

The Rebate Programs are administered as part of the prescription drug affordability provisions of the Inflation Reduction Act (the “IRA”), which is aimed at “lower[ing] out-of-pocket drug costs for people with Medicare and improv[ing] the sustainability of the Medicare program for current and future generations.” [1]

article thumbnail

What’s Expected to Drive Up Health Plan Costs in 2025: GLP-1s, Behavioral Health, and Inflationary Pressures for Hospitals and Doctors – PwC’s Behind the Numbers 2025

Jane Sarashon

We’ve discussed the hockey-stick rise in the adoption and persistent use of GLP-1 drugs for managing diabetes and obesity here in Health Populi. This graph diagrams utilization, unit cost, and cost as a percent of overall medical cost trend: note that by the middle of 2023, GLP-1 drug costs for Group health plan members comprised 13.6%

Doctors 59
article thumbnail

New York Enacts Landmark Legislation Regulating PBMs

Health Care Law Brief

On December 31, 2021, New York Governor Kathy Hochul signed landmark legislation to increase the transparency of prescription drug pricing and to establish requirements on pharmacy middlemen. Failure to obtain a license by 2023 could result in a cease and desist order from DFS and financial penalties. 1] [link].

article thumbnail

How Will the “New” Health Economy Fare in a Macro-Economic Downturn?

Health Populi

Add to that scenario a growing consensus for a likely recession in 2023. health care system not seen since the 1968 creation of Medicare, coupled with decreased reimbursement due to health care reform. Consumers will be facing greater medical price inflation in 2023 for health insurance plans, based on the latest forecast from WTW.